智通财经APP获悉，创胜集团-B(06628)早盘跌超9%，截至发稿，跌4.13%，报5.11港元，成交额1437.94 万港元。 华兴证券此前发布研报称，近期，创胜集团在研发和临床方面取得重大突破。根据2025 ASCO数据， TST001与PD1/CAPOX联用一线治疗胃癌，82例入组患者的中位生存期(mOS)达到20.4个月。根据公司 近期业绩会，在获得监管批准后，TST001针对胃癌/胃食管癌即将启动全球III期临床试验。抗骨质疏松 药物Blosozumab(TST002)在中国进入II期临床并取得积极早期结果。此外，针对肿瘤和自身免疫疾病的 首创ADC及双抗药物也取得早期临床进展。 消息面上，创胜集团-发布公告，拟配售1440万股股份，每股配售价为4.33港元，较9月9日收市价每股 5.33港元折让约18.76%。配售所得款项净额则约5934万港元，其中40%用于TST001及TST002等管线资 产的临床开发；30%用于推进最具前景且具有近期对外许可潜力的临床前阶段管线资产，包括 TST801、TST013及TST786等；30%将用于营运资金及一般用途，从而提高公司的财务稳健性，包括但 不限于一 ...

来源：新浪港股-好仓工作室 创胜集团是一家专注于药物研发的企业。所得款项中，约 2370 万港元将用于 TST001 及 TST002 等管 线资产的临床开发；约 1780 万港元用于推进最具前景且具有近期对外许可潜力的临床前阶段管线资 产；约 1780 万港元用于营运资金及一般用途。本次发行根据股东大会授予的一般授权实施，预计于 2025 年 9 月 17 日完成。 点击查看公告原文>> 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 2025 年 9 月 10 日，创胜集团（股份代号：6628）公告称，通过一般授权以"配售新股"方式融资，发行 14,400,000 股（约 0.1 亿股），募集约 6240 万港元（扣除费用后净得约 5930 ...

配售所得款项总额预期约6235万港元，所得款项净额则约5934万港元。公司拟将认购事项所得款项净额 按下列方式动用：(i)40%用于TST001及TST002等管线资产的临床开发;(ii)30%用于推进最具前景且具有 近期对外许可潜力的临床前阶段管线资产，包括TST801、TST013及TST786等;(iii)30%将用于营运资金 及一般用途，从而提高公司的财务稳健性，包括但不限于一般业务运营及业务发展等。 创胜集团-B(06628)发布公告，于2025年9月10日，公司拟配售1440万股股份，占于完成配售后经扩大已 发行股份(不包括库存股份)总数约3.20%。配售价为每股配售股份4.33港元，较9月9日收市价每股5.33港 元折让约18.76%。 ...

配售所得款项总额预期约6235万港元，所得款项净额则约5934万港元。公司拟将认购事项所得款项净额 按下列方式动用：(i)40%用于TST001及TST002等管线资产的临床开发;(ii)30%用于推进最具前景且具有 近期对外许可潜力的临床前阶段管线资产，包括TST801、TST013及TST786等;(iii)30%将用于营运资金 及一般用途，从而提高公司的财务稳健性，包括但不限于一般业务运营及业务发展等。 智通财经APP讯，创胜集团-B(06628)发布公告，于2025年9月10日，公司拟配售1440万股股份，占于完 成配售后经扩大已发行股份(不包括库存股份)总数约3.20%。配售价为每股配售股份4.33港元，较9月9日 收市价每股5.33港元折让约18.76%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致之任何損失承擔任何責任 本公告或其任何副本皆不得在美國或在發放或分派本公告可能違法的任何其他司法權區境內直 接或間接發放或分派。 本公告僅供參考，不構成收購、購買或認購本公司任何證券的邀請或要約。 本公告並非在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公告所述證券並 未且將不會根據《1933年美國證券法》（「美國證券法」）登記，亦不會在美國提呈或出售，除非 根據美國證券法作出登記或獲豁免或為毋須根據美國證券法作出登記之交易。本公司無意根據 美國證券法登記本公告內所指之任何證券，或在美國進行證券之公開發售。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 根據一般授權配售新股 獨家整體協調人、獨家全球協調人兼獨家配售代理 中銀國際亞洲有限公司 1 董事會宣佈，於2025年9月10日（交易時段前），本公司及配售代理訂立配售協 議， ...

致：香港交易及結算所有限公司 公司名稱: 創勝集團醫藥有限公司（以存續方式於開曼群島註冊的有限公司） 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 本月底法定/註冊股本總額： USD 1,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06628 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 434,897,445 | | 2,516,500 | | 437,413,945 | | 增加 / 減少 (-) | | | 62,000 | | 0 | | ...

Group 1 - The Hang Seng Index fell by 0.4%, while the Hang Seng Tech Index decreased by 0.54%, with a total turnover of 152 billion HKD in the Hong Kong stock market during the morning session [1] - The Hang Seng Biotechnology Index rose by 1%, with notable gains from companies such as MicroPort Scientific Corporation (02252) up by 10%, and Four Seasons Medicine (00460) up by 8% [1] Group 2 - MicroPort Scientific Corporation (02252) saw a rise of over 10%, indicating renewed interest in the robotics industry and steady progress in the company's commercialization efforts [2] - Dongyang Sunshine Pharmaceutical (06887) increased by nearly 7%, reporting a mid-term gross profit of 1.468 billion HKD, with key data on Ifenprodil presented at the US IPF summit [2] - Chuangsheng Group-B (06628) surged over 28%, with a mid-term net loss narrowing by 17.9%, and TST001 research data making its debut at ASCO [2] - Kingsoft Holdings (03918) rose by over 6%, with first-half performance exceeding market expectations, although uncertainties remain regarding the Naga3 project according to Citigroup [2] - Green Power Environmental (01330) increased by over 7%, with a 24.49% year-on-year increase in net profit attributable to shareholders, driven by its gas supply business [2] - Hylink Technology (01860) rose by 7.9%, with first-half revenue increasing by 40% year-on-year, and institutions optimistic about the continued release of the Mintegral platform's flywheel effect [2] - Zhi Zi Cheng Technology (09911) rose by over 6%, with first-half net profit nearly doubling, and the group's gross profit margin expected to improve significantly year-on-year [2] - Four Seasons Medicine (00460) rose by over 7%, achieving profitability in the first half and making substantial progress in its AI + medical beauty strategic layout [2] - Guofu Quantum (00290) increased by 6.86%, with a cumulative increase of nearly 1.8 times this year, collaborating with Huajian Medical to advance RWA ecosystem construction [2] - New Idea Network Group (01686) fell by over 17% post-results, with annual net profit increasing by 8% to 979 million HKD [2]

Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant intraday surge of over 28%, reaching a price of 4.9 HKD, with a trading volume of 21.44 million HKD. The company reported a 40.6% year-on-year decline in revenue to 2.711 million HKD for the mid-year 2025, while the loss narrowed by 17.9% to approximately 110 million HKD, resulting in a loss per share of 0.27 HKD. The revenue decline was primarily attributed to a reduction in CDMO services [1][2]. Group 1 - Chuangsheng Group-B's mid-year 2025 revenue was 2.711 million HKD, a decrease of 40.6% year-on-year [1] - The company reported a loss of approximately 110 million HKD, which is a 17.9% improvement compared to the previous year [1] - The loss per share for the period was 0.27 HKD [1] Group 2 - Recent breakthroughs in research and clinical trials were highlighted, particularly the TST001 treatment for gastric cancer, which showed a median overall survival (mOS) of 20.4 months in a study involving 82 patients [1] - In a subgroup of 26 patients with high CLDN18.2 expression, the mOS was 21.7 months, with a median progression-free survival (mPFS) of 16.6 months and a confirmed objective response rate (cORR) of 68% [1] - The company is set to initiate a global Phase III clinical trial for TST001 targeting gastric and gastroesophageal cancers following regulatory approval [2] Group 3 - The osteoporosis drug Blosozumab (TST002) has entered Phase II clinical trials in China, yielding positive early results [2] - The company has also made early clinical progress with innovative ADC and bispecific antibody drugs targeting tumors and autoimmune diseases [2]

Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant stock price increase of 28.27%, reaching HKD 4.9, with a trading volume of HKD 21.44 million, following the announcement of its 2025 interim results which showed a revenue decline of 40.6% year-on-year [1] Financial Performance - The company reported a revenue of HKD 2.711 million for the 2025 interim period, a decrease of 40.6% compared to the previous year [1] - The net loss for the period was approximately HKD 110 million, which represents a 17.9% reduction year-on-year [1] - Earnings per share (EPS) showed a loss of HKD 0.27 [1] Clinical Developments - Chuangsheng Group has made significant breakthroughs in research and clinical trials, particularly with TST001 in combination with PD1/CAPOX for first-line treatment of gastric cancer, achieving a median overall survival (mOS) of 20.4 months among 82 enrolled patients [1] - In a subgroup of 26 patients with high expression of CLDN18.2, the mOS was 21.7 months, with a median progression-free survival (mPFS) of 16.6 months and a confirmed objective response rate (cORR) of 68%, with a median duration of response (mDoR) of 16.5 months [1] Future Clinical Trials - Following recent performance meetings, the company plans to initiate a global Phase III clinical trial for TST001 targeting gastric and gastroesophageal cancers upon receiving regulatory approval [2] - The osteoporosis drug Blosozumab (TST002) has entered Phase II clinical trials in China, showing positive early results [2] - The company is also advancing early clinical progress on innovative ADC and bispecific antibody drugs targeting tumors and autoimmune diseases [2]

创胜集团-B(06628)公布2025年中期业绩，收入271.1万元，同比减少40.6%;期内亏损约1.1亿元，同比收 窄17.9%;每股亏损0.27元。 公告称，收入减少主要由于CDMO服务减少。 ...